Trial Profile
Comparison of Efficacy and Safety of Icaritin Versus Cinobufotalin in First-line Treatment of Advanced Hepatocellular Carcinoma Subjects: a Multicenter, Randomized, Double-blind, Double-dummy Phase III Clinical Trial
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 27 Sep 2023
Price :
$35
*
At a glance
- Drugs Icaritin (Primary) ; Huachansu
- Indications Liver cancer
- Focus Registrational; Therapeutic Use
- Sponsors Beijing Shenogen Biomedical
- 08 Jun 2021 Interim results (n=283) presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 05 Jan 2021 Planned number of patients changed from 280 to 312.
- 05 Jan 2021 Planned End Date changed from 1 Aug 2019 to 30 Dec 2022.